metformin has been researched along with mdv 3100 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| DeVere White, RW; Evans, CP; Gao, AC; Kung, HJ; Lara, PN; Nguyen, HG; Shi, XB; Tilki, D; Yang, JC | 1 |
| Bi, G; Do, K; Geary, K; Jiang, J; Lan, W; Li, Y; Liu, G; Liu, Q; Tong, D; Xu, J; Zhang, D; Zhang, J; Zhang, Y | 1 |
| Hill, J; McCabe, C; North, SA; Paulden, M; Usmani, N; Venner, P | 1 |
| Armstrong, A; Beer, TM; Carles, J; Crumbaker, M; de Bono, J; Duggan, W; Fizazi, K; Gillessen, S; Hussain, M; Joshua, AM; Lin, P; Russell, D; Scher, HI; Sternberg, CN; Sugg, J; Tombal, B | 1 |
1 review(s) available for metformin and mdv 3100
| Article | Year |
|---|---|
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER.
Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metformin; Nitriles; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2022 |
4 other study(ies) available for metformin and mdv 3100
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model.
Topics: Androgen Receptor Antagonists; Animals; Autophagy; Benzamides; Cell Line, Tumor; Chloroquine; Clomipramine; Gene Expression Regulation, Neoplastic; Humans; Male; Metformin; Mice; Mice, SCID; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Interactions; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Hypoglycemic Agents; Male; Metformin; Mice; Mice, Nude; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; STAT3 Transcription Factor; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays | 2017 |
Cost-effectiveness analysis of metformin with enzalutamide in the metastatic castrate-resistant prostate cancer setting.
Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Male; Markov Chains; Metformin; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2019 |